Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  De Giovanni, Carla ^a   Nicoletti, Giordano ^b   Quaglino, Elena ^c   Landuzzi, Lorena ^b   Palladini, Arianna ^a   Ianzano, Marianna Lucia ^a   Dall'Ora, Massimiliano ^a   Grosso, Valentina ^a   Ranieri, Dario ^a   Laranga, Roberta ^a   Croci, Stefania ^a   Amici, Augusto ^d   Penichet, Manuel L ^e   Iezzi, Manuela ^f   Cavallo, Federica ^c   Nanni, Patrizia ^a   Lollini, Pier Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF CAMERINO   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CANCER VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; GAMMA INTERFERON; INTERLEUKIN 12;

ADOPTIVE TRANSFER; ANIMAL; ANTIBODY PRODUCTION; BIOSYNTHESIS; BLOOD; CYTOLOGY; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; MAMMARY NEOPLASMS, ANIMAL; MCF 7 CELL LINE; MOUSE; PATHOLOGY; SPLEEN; TRANSGENIC MOUSE; TRANSPLANTATION; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; MAMMARY NEOPLASMS, ANIMAL; MCF-7 CELLS; MICE; MICE, TRANSGENIC; RECEPTOR, ERBB-2; SPLEEN; VACCINES, DNA;

EID: 84892715075     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3602     Document Type: Article

References (29)

1. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368. 10.1634/theoncologist.2008-0230, 19346299.
2. Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI, Maihle NJ. EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem 2012, 4:447-469. 10.4155/fmc.12.11, 22416774.
3. Lorenzen S, Lordick F. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?. Curr Opin Oncol 2011, 23:396-402. 10.1097/CCO.0b013e3283469567, 21505336.
4. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006, 6:204-216. 10.1038/nrc1815, 16498443.
5. Lollini PL, Nicoletti G, Landuzzi L, Cavallo F, Forni G, De Giovanni C, Nanni P. Vaccines and other immunological approaches for cancer immunoprevention. Curr Drug Targets 2011, 12:1957-1973. 10.2174/138945011798184146, 21158706.
6. Farkas AM, Finn OJ. Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. Semin Immunol 2010, 22:125-131. 10.1016/j.smim.2010.03.003, 20403708.
7. Ladjemi MZ, Jacot W, Chardès T, Pèlegrin A, Navarro-Teulon I. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 2010, 59:1295-1312. 10.1007/s00262-010-0869-2, 2933838, 20532501.
8. Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER-2/neu as a target for cancer vaccines. Immunotherapy 2010, 2:213-226. 10.2217/imt.09.89, 20635929.
9. Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 2012, 118:4354-4362. 10.1002/cncr.26734, 3330145, 22252842.
10. Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, Forni G. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998, 188:589-596. 10.1084/jem.188.3.589, 2212479, 9687535.
11. Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G, Lollini PL. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 2001, 194:1195-1205. 10.1084/jem.194.9.1195, 2195980, 11696586.
12. De Giovanni C, Nicoletti G, Landuzzi L, Astolfi A, Croci S, Comes A, Ferrini S, Meazza R, Iezzi M, Di Carlo E, Musiani P, Cavallo F, Nanni P, Lollini PL. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res 2004, 64:4001-4009. 10.1158/0008-5472.CAN-03-2984, 15173014.
13. Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Antognoli A, Landuzzi L, Fabbi M, Ferrini S, Musiani P, Iezzi M, De Giovanni C, Lollini PL. Antimetastatic activity of a preventive cancer vaccine. Cancer Res 2007, 67:11037-11044. 10.1158/0008-5472.CAN-07-2499, 18006850.
14. Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 2004, 64:2858-2864. 10.1158/0008-5472.CAN-03-2962, 15087404.
15. De Giovanni C, Nicoletti G, Palladini A, Croci S, Landuzzi L, Antognoli A, Murgo A, Astolfi A, Ferrini S, Fabbi M, Orengo AM, Amici A, Penichet ML, Aurisicchio L, Iezzi M, Musiani P, Nanni P, Lollini PL. A multi-DNA preventive vaccine for p53/neu-driven cancer syndrome. Hum Gene Ther 2009, 20:453-464. 10.1089/hum.2008.172, 19215191.
16. Quaglino E, Mastini C, Amici A, Marchini C, Iezzi M, Lanzardo S, De Giovanni C, Montani M, Lollini PL, Masucci G, Forni G, Cavallo F. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res 2010, 70:2604-2612. 10.1158/0008-5472.CAN-09-2548, 20332241.
17. Piechocki MP, Ho YS, Pilon S, Wei WZ. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 2003, 171:5787-5794.
18. Jacob JB, Quaglino E, Radkevich-Brown O, Jones RF, Piechocki MP, Reyes JD, Weise A, Amici A, Wei WZ. Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity. Cancer Res 2010, 70:119-128. 10.1158/0008-5472.CAN-09-2554, 20048073.
19. Finkle D, Quan ZR, Asghari V, Kloss J, Ghaboosi N, Mai E, Wong WL, Hollingshead P, Schwall R, Koeppen H, Erickson S. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 2004, 10:2499-2511. 10.1158/1078-0432.CCR-03-0448, 15073130.
20. Ladjemi MZ, Chardes T, Corgnac S, Garambois V, Morisseau S, Robert B, Bascoul-Mollevi C, Ait Arsa I, Jacot W, Pouget JP, Pelegrin A, Navarro-Teulon I. Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice. Breast Cancer Res 2011, 13:R17. 10.1186/bcr2826, 3109586, 21294885.
21. Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML, Grosso V, Stivani V, Antognoli A, Lamolinara A, Landuzzi L, di Tomaso E, Iezzi M, De Giovanni C, Lollini PL. Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor. PLoS One 2012, 7:e39626. 10.1371/journal.pone.0039626, 3380859, 22737248.
22. Nanni P, Nicoletti G, Landuzzi L, Croci S, Murgo A, Palladini A, Antognoli A, Ianzano ML, Stivani V, Grosso V, Maira SM, García-Echeverría C, Scotlandi K, De Giovanni C, Lollini PL. High metastatic efficiency of human sarcoma cells in Rag2/γc double knockout mice provides a powerful test system for antimetastatic targeted therapy. Eur J Cancer 2010, 46:659-668. 10.1016/j.ejca.2009.11.018, 20031388.
23. Palladini A, Nicoletti G, Pappalardo F, Murgo A, Grosso V, Stivani V, Ianzano ML, Antognoli A, Croci S, Landuzzi L, De Giovanni C, Nanni P, Motta S, Lollini PL. In silico modeling and in vivo efficacy of cancer-preventive vaccinations. Cancer Res 2010, 70:7755-7763. 10.1158/0008-5472.CAN-10-0701, 20924100.
24. Marchini C, Gabrielli F, Iezzi M, Zenobi S, Montani M, Pietrella L, Kalogris C, Rossini A, Ciravolo V, Castagnoli L, Tagliabue E, Pupa SM, Musiani P, Monaci P, Menard S, Amici A. The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse. PLoS One 2011, 6:e18727. 10.1371/journal.pone.0018727, 3084693, 21559085.
25. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992, 89:10578-10582. 10.1073/pnas.89.22.10578, 50384, 1359541.
26. Nanni P, Landuzzi L, Nicoletti G, De Giovanni C, Rossi I, Croci S, Astolfi A, Iezzi M, Di Carlo E, Musiani P, Forni G, Lollini PL. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-γ and B cell dependent. J Immunol 2004, 173:2288-2296.
27. Nanni P, Gatta V, Menotti L, De Giovanni C, Ianzano M, Palladini A, Grosso V, Dall'ora M, Croci S, Nicoletti G, Landuzzi L, Iezzi M, Campadelli-Fiume G, Lollini PL. Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. PLoS Pathog 2013, 9:e1003155. 10.1371/journal.ppat.1003155, 3561254, 23382683.
28. Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med 2010, 8:53. 10.1186/1479-5876-8-53, 2903523, 20529245.
29. Rolla S, Nicoló C, Malinarich S, Orsini M, Forni G, Cavallo F, Ria F. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 2006, 177:7626-7633.